Page URL:

Desktop machine can sequence a genome in one day for £650

16 January 2012
Appeared in BioNews 640

A US biotechnology firm has unveiled an automated desktop DNA sequencer that can decode the sequence of the human genome in one day for as little as $1,000 (£650).

Given its first public viewing at a consumer electronics show in Las Vegas, Life Technologies Corporation's Ion Proton sequencer uses microchips similar to those found in digital cameras to detect chemical changes rather than light. The device costs just under £100,000.

Getting the cost of sequencing down to under the $1,000 per genome has long been considered a milestone in the development of personalised medicine. The Ion Proton sequencer could make it feasible for research institutes and hospitals to sequence large sections of DNA rapidly, and at an affordable price. Three major US research institutes - the Baylor College of Medicine, the Yale School of Medicine and the Broad Institute in Massachusetts – have already placed orders for the machine.

'A genome sequence for $1,000 was a pipe dream just a few years ago', says Richard Gibbs, director of the Human Genome Sequencing Center at Baylor. 'A $1,000 genome in less than one day was not even on the radar, but will transform the clinical applications of sequencing'.

The first batch of microchips for the machine will have the capability to sequence exomes, the part of human DNA that actually codes for functional proteins. The company plans to release a second-generation chip at the end of 2012 with the ability to decode the entire three billion base-pair human DNA sequence.

The availability of low-cost and rapid DNA sequencers is likely to have a major impact on public healthcare. For instance, it will allow rapid diagnosis of disease markers, such as those for breast and prostate cancer, Alzheimer's disease and cystic fibrosis. It might even help doctors prescribe medication for patients, using gene markers to distinguish between patients who are able to tolerate a particular drug and those who might be more susceptible to side-effects.

However, a large chunk of the information derived from the sequencers might still be hard to decipher until we are better able to understand the links between genetics and disease. As Chad Nussbaum, co-director of the Genome Sequencing and Analysis Program at the Broad Institute, commented: 'You've got to glean the news out of the genome and you've got to give it to the doctor in a usable way'.

Ethical concerns have been also raised about the impact of accessible genome sequencing. 'We need to be careful how we utilise this information', said Richard Lifton, chairman of the genetics department at Yale University. 'Do you tell a newborn's parent's [of their child's] apoE status?' ApoE is a form of a gene which raises the risk of Alzheimer's disease.

Another biotechnology firm, Illumina, has announced plans for a similar benchtop sequencer, which is due for launch later this year.

Company announces low-cost DNA decoding machine
Associated Press |  10 January 2012
Company announces low-cost DNA decoding machine
USA Today |  11 January 2012
Have your own genome decoded – for just £650
Independent |  11 January 2012
How Life Technologies will sequence the human genome for $1,000 (video)
MedCity News |  13 January 2012
Ion Proton: An Even Bigger Leap for Human Genome Sequencing
The Atlantic |  15 January 2012
Low-cost DNA reader announced: What does it mean for patients?
CBS News |  11 January 2012
20 January 2014 - by Dr Rachael Panizzo 
The $1,000 genome may have arrived, an achievement which would mark a significant milestone in the application of genetic science...
30 July 2012 - by Dr Nadeem Shaikh 
A US company has taken up the challenge to sequence 100 genomes in 30 days...
16 July 2012 - by Daryl Ramai 
Technology that relies on less DNA to more accurately sequence people's genomes has been unveiled by a US biotech company...
30 April 2012 - by Ruth Saunders 
The standoff between Roche and Illumina, which provides services and equipment for genetic analysis, finally came to an end last week as the Swiss pharmaceuticals giant ended efforts for a hostile takeover bid...
27 February 2012 - by Ayesha Jadoon 
A handheld device for sequencing DNA on the move has been unveiled by UK company Oxford Nanopore. The single-use MinION tool resembles a USB drive in size and shape, and the company hopes it will be put into routine use by clinicians and researchers alike...
9 January 2012 - by Rachel Lloyd 
Personalised healthcare could be one step closer this year, as doctors from the prestigious US Mayo Clinic embark on a project to sequence the full genetic code of thousands of people...
10 October 2011 - by Oliver Timmis 
The Faroe Islands is set to become the first region to sequence the genome of its entire population....
3 May 2011 - by Mehmet Fidanboylu 
Two US studies have demonstrated how whole-genome screening can help improve cancer treatment and diagnosis. The researchers claim to have taken a major step towards using this type of screening to help predict patients' responses to different treatments based on their genetics...
22 February 2010 - by Maren Urner 
A fast, low cost DNA test that can reveal a person's chances of developing certain inherited diseases could soon be a reality, scientists in Scotland have said. The test involves testing a patient's saliva to identify disease-related variations in their genetic code and is faster and cheaper than conventional methods, according to the study published in the journal Angewandte Chemie....
15 June 2009 - by Adam Fletcher 
The age of affordable genome sequencing is inching ever closer, spurred on last week by the announcement that San Diego biotech firm Illumina is launching its personal sequencing service for under $50,000. Speaking at the Consumer Genetics Show in Boston, Massachusetts, US, Jay Flatley - the president and CEO of Illumina - unveiled a service that represents the first time that an individual's genome can be sequenced so thoroughly, for such a (relatively) low price....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.